Biotech News

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RxSight (RXST)RxSightEarnings

ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook. Second Quarter 2026 Highlights Total company Q2 revenue of $33.7 million, which includes

Related news

RxSight

Adjustable Cataract Lenses RxSight is an ophthalmic medical-device company focused on customized vision after cataract surgery. Light Adjustable Lens System The system combines an implantable Light Adjustable Lens with a Light Delivery Device. After surgery, physicians use ultraviolet light treatments to modify the lens and refine the...

Recent company news

Stock data

Close
6.08 USD
Market cap
204.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States